Market Overview

Morning Market Losers

Related GTXI
GTx Announces Enrollment of First Patient in Phase 2 Clinical Trial of Enobosarm in Triple Negative Breast Cancer
US Stock Futures Rise Ahead Of Housing, Consumer Confidence Data
Related STEM
Valeant CEO Addresses Investor Concerns In Letter; Will It Help The Stock Price?
StemCells, Inc. Transplants First Patient in Phase II Clinical Trial for Dry Age-Related Macular Degeneration

GTX (NASDAQ: GTXI) plummeted 15.96% to $1.58 after the company announced its plans to lower 60% of its workforce.

StemCells (NASDAQ: STEM) dropped 14.29% to $1.44 after the company received the FDA authorization of IND for spinal cord injury.

Star Bulk Carriers (NASDAQ: SBLK) dropped 12.12% to $8.98 after the company announced a public offering of common stock.

Team (NYSE: TISI) dropped 11.53% to $35.39 after the company lowered its annual earnings outlook.

Posted-In: market losersNews Movers & Shakers Intraday Update Markets


Related Articles (GTXI + SBLK)

Get Benzinga's Newsletters